| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00418-018-1636-2 |
| P698 | PubMed publication ID | 29392395 |
| P50 | author | Takehito Ono | Q62752490 |
| P2093 | author name string | Tomoki Nakashima | |
| P2860 | cites work | The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis | Q24297505 |
| Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1 | Q24300916 | ||
| Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone | Q24309351 | ||
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| Tmem64 modulates calcium signaling during RANKL-mediated osteoclast differentiation | Q24315189 | ||
| Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis | Q24324701 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6 | Q24537518 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification | Q24600356 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes | Q24628843 | ||
| HCO3-/Cl- anion exchanger SLC4A2 is required for proper osteoclast differentiation and function | Q24644323 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Fracture healing: mechanisms and interventions | Q26851958 | ||
| Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity | Q27635130 | ||
| Structural and functional insights of RANKL-RANK interaction and signaling | Q27661741 | ||
| RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor | Q27674275 | ||
| UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
| Osteopetrosis and its relevance for the discovery of new functions associated with the skeleton | Q28085259 | ||
| Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families | Q28137631 | ||
| Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice | Q28140546 | ||
| Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival | Q28142897 | ||
| Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man | Q28201425 | ||
| Osteoimmunology in Bone Fracture Healing. | Q39396818 | ||
| TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation | Q40119268 | ||
| Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. | Q40230484 | ||
| Murine dendritic cell transdifferentiation into osteoclasts is differentially regulated by innate and adaptive cytokines | Q40241909 | ||
| Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice | Q28207641 | ||
| Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene | Q28210464 | ||
| Matrix-embedded cells control osteoclast formation | Q28247746 | ||
| Evidence for osteocyte regulation of bone homeostasis through RANKL expression | Q28247757 | ||
| Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone | Q28267634 | ||
| The transcription factor Jdp2 controls bone homeostasis and antibacterial immunity by regulating osteoclast and neutrophil differentiation | Q28280363 | ||
| Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency | Q28284581 | ||
| Ventastega curonica and the origin of tetrapod morphology | Q28285249 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| Heritable disorders of the RANKL/OPG/RANK signaling pathway | Q28299674 | ||
| RANKL-induced DC-STAMP is essential for osteoclastogenesis | Q28504881 | ||
| Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects | Q28505493 | ||
| Tmem178 acts in a novel negative feedback loop targeting NFATc1 to regulate bone mass | Q28506158 | ||
| DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells | Q28506839 | ||
| Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion | Q28512093 | ||
| ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function | Q28512374 | ||
| Immune complexes regulate bone metabolism through FcRγ signalling | Q28512966 | ||
| TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human | Q28590831 | ||
| Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption | Q28592760 | ||
| Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis | Q28593488 | ||
| Hematopoietic stem cell: self-renewal versus differentiation | Q29396498 | ||
| Missing pieces in the NF-kappaB puzzle | Q29547864 | ||
| Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice | Q29547898 | ||
| Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts | Q29618116 | ||
| c-Src links a RANK/αvβ3 integrin complex to the osteoclast cytoskeleton | Q30010102 | ||
| NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism | Q30157499 | ||
| Differential roles of MAPK kinases MKK3 and MKK6 in osteoclastogenesis and bone loss | Q30415395 | ||
| Microgravity promotes osteoclast activity in medaka fish reared at the international space station | Q30665836 | ||
| Blimp1-mediated repression of negative regulators is required for osteoclast differentiation | Q33733731 | ||
| The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. | Q33794960 | ||
| FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner | Q34014506 | ||
| Activating transcription factor 4 regulates osteoclast differentiation in mice. | Q34028709 | ||
| Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis | Q34102750 | ||
| LOX Fails to Substitute for RANKL in Osteoclastogenesis | Q40547452 | ||
| The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells | Q40599606 | ||
| Phosphoproteomic analysis of kinase-deficient mice reveals multiple TAK1 targets in osteoclast differentiation | Q40808939 | ||
| Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement | Q40841743 | ||
| Osteocyte regulation of orthodontic force-mediated tooth movement via RANKL expression. | Q41459925 | ||
| Role of osteoblasts in hormonal control of bone resorption—A hypothesis | Q41551873 | ||
| Osteoprotection by semaphorin 3A. | Q41791623 | ||
| Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis | Q41995909 | ||
| Phosphatidylethanolamine dynamics are required for osteoclast fusion | Q42290733 | ||
| Autoamplification of NFATc1 expression determines its essential role in bone homeostasis | Q42972503 | ||
| Quantification of the expression levels of lysosomal cysteine proteinases in purified human osteoclastic cells by competitive RT-PCR. | Q43580089 | ||
| Vav3 regulates osteoclast function and bone mass | Q45265424 | ||
| Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. | Q46711436 | ||
| Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12. | Q46840295 | ||
| The axial skeleton of the Devonian tetrapod Ichthyostega | Q47253242 | ||
| Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis | Q47761859 | ||
| Alteration of RANKL-induced osteoclastogenesis in primary cultured osteoclasts from SERCA2+/- mice | Q47871560 | ||
| Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. | Q47944184 | ||
| Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. | Q48083226 | ||
| DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway. | Q48222451 | ||
| Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. | Q50335578 | ||
| Real-time intravital imaging of pH variation associated with osteoclast activity. | Q51301045 | ||
| Epigenetic regulation of osteoclast differentiation: possible involvement of Jmjd3 in the histone demethylation of Nfatc1. | Q51547582 | ||
| Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. | Q52537176 | ||
| Osteoblastic cells are involved in osteoclast formation. | Q54374668 | ||
| Immune Interactions with CD4+ T Cells Promote the Development of Functional Osteoclasts from Murine CD11c+ Dendritic Cells | Q57184758 | ||
| NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1 | Q57675122 | ||
| JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms | Q58326878 | ||
| The -Isoform of p38 MAPK Specifically Regulates Arthritic Bone Loss | Q61900817 | ||
| Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand | Q64378984 | ||
| The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells | Q69541163 | ||
| The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants | Q73531419 | ||
| Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines | Q74269794 | ||
| Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand | Q79181865 | ||
| v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation | Q79383955 | ||
| MafB negatively regulates RANKL-mediated osteoclast differentiation | Q79421924 | ||
| Phenotypic characteristics of bone in carbonic anhydrase II-deficient mice | Q80444950 | ||
| Continuous activation of G alpha q in osteoblasts results in osteopenia through impaired osteoblast differentiation | Q81152482 | ||
| Osteoclast stimulatory transmembrane protein and dendritic cell–specific transmembrane protein cooperatively modulate cell–cell fusion to form osteoclasts and foreign body giant cells | Q83454126 | ||
| The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo | Q84136412 | ||
| Human mesenchymal stromal cells express CD14 cross-reactive epitopes | Q84514622 | ||
| Eighth Bone Quality Seminar Proceedings 2013 | Q88012211 | ||
| RANKL-Independent Osteoclastogenesis: A Long-Standing Controversy | Q89229670 | ||
| Macrophages and osteoclasts stem from a bipotent progenitor downstream of a macrophage/osteoclast/dendritic cell progenitor | Q89777426 | ||
| Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond | Q34366449 | ||
| Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo | Q34420830 | ||
| A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss | Q34567407 | ||
| Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids | Q34790932 | ||
| Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 | ||
| Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice | Q35607627 | ||
| TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. | Q35760837 | ||
| Stage-specific functions of leukemia/lymphoma-related factor (LRF) in the transcriptional control of osteoclast development | Q35787174 | ||
| Mechanobiology of the skeleton. | Q36141041 | ||
| Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis | Q36368706 | ||
| Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors | Q36375584 | ||
| Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis | Q36402845 | ||
| I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss | Q36402985 | ||
| TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. | Q36404187 | ||
| TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis | Q36560045 | ||
| Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation | Q36580426 | ||
| Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. | Q36760597 | ||
| Role of Thyroid Hormones in Skeletal Development and Bone Maintenance | Q36773018 | ||
| Dissociation between bone resorption and bone formation in osteopenic transgenic mice | Q36800774 | ||
| Osteoclast precursors in murine bone marrow express CD27 and are impeded in osteoclast development by CD70 on activated immune cells | Q37049540 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. | Q37126990 | ||
| RANK, RANKL and osteoprotegerin in bone biology and disease. | Q37199218 | ||
| NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). | Q37302319 | ||
| Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis | Q37370702 | ||
| Enhanced but hypofunctional osteoclastogenesis in an autosomal dominant osteopetrosis type II case carrying a c.1856C>T mutation in CLCN7. | Q37449518 | ||
| Acute transcriptional up-regulation specific to osteoblasts/osteoclasts in medaka fish immediately after exposure to microgravity | Q37525966 | ||
| p38α MAPK regulates proliferation and differentiation of osteoclast progenitors and bone remodeling in an aging-dependent manner | Q37739585 | ||
| Advances in osteoclast biology: old findings and new insights from mouse models | Q37850997 | ||
| V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption | Q38015040 | ||
| Emerging role of primary cilia as mechanosensors in osteocytes | Q38064200 | ||
| Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos | Q38342636 | ||
| Imaging of Paget's disease of bone | Q38985801 | ||
| Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 325-341 | |
| P577 | publication date | 2018-02-01 | |
| P1433 | published in | Histochemistry and Cell Biology | Q1524012 |
| P1476 | title | Recent advances in osteoclast biology | |
| P478 | volume | 149 |
| Q89964126 | Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1 |
| Q64983678 | Artesunate, an Anti-Malaria Agent, Attenuates Experimental Osteoarthritis by Inhibiting Bone Resorption and CD31hiEmcnhi Vessel Formation in Subchondral Bone. |
| Q92550919 | Cervus and cucumis peptides ameliorates bone erosion in experimental arthritis by inhibiting osteoclastogenesis |
| Q97066965 | Deciphering the underlying mechanism of Xianlinggubao capsule against osteoporosis by network pharmacology |
| Q92257336 | Fermented Sea Tangle (Laminaria japonica Aresch) Suppresses RANKL-Induced Osteoclastogenesis by Scavenging ROS in RAW 264.7 Cells |
| Q64073039 | Forceful mastication activates osteocytes and builds a stout jawbone |
| Q64264445 | Hematopoietic or Osteoclast-Specific Deletion of Syk Leads to Increased Bone Mass in Experimental Mice |
| Q50420732 | In focus in HCB: Hard Tissue Biology. |
| Q64085314 | Interleukin-27 prevents LPS-induced inflammatory osteolysis by inhibiting osteoclast formation and function |
| Q89977149 | METTL3 Modulates Osteoclast Differentiation and Function by Controlling RNA Stability and Nuclear Export |
| Q90182318 | Nrf2 is required for suppressing osteoclast RANKL-induced differentiation in RAW 264.7 cells via inactivating cannabinoid receptor type 2 with AM630 |
| Q98205366 | Oridonin ameliorates inflammation-induced bone loss in mice via suppressing DC-STAMP expression |
| Q89820667 | Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System |
| Q96305136 | Osteoimmunomodulatory effects of biomaterial modification strategies on macrophage polarization and bone regeneration |
| Q90729095 | Osteoporosis: Mechanism, Molecular Target, and Current Status on Drug Development |
| Q58746996 | Peripheral blood monocytes show increased osteoclast differentiation potential compared to bone marrow monocytes |
| Q91941325 | Piceatannol attenuates RANKL-induced osteoclast differentiation and bone resorption by suppressing MAPK, NF-κB and AKT signalling pathways and promotes Caspase3-mediated apoptosis of mature osteoclasts |
| Q64065836 | Protective Effects of Fermented Oyster Extract against RANKL-Induced Osteoclastogenesis through Scavenging ROS Generation in RAW 264.7 Cells |
| Q89666841 | RANKL biology: bone metabolism, the immune system, and beyond |
| Q93108751 | The Role of Exosomes in Bone Remodeling: Implications for Bone Physiology and Disease |
| Q91611014 | The Role of Macrophage in the Pathogenesis of Osteoporosis |
| Q92132065 | Tussilagone Inhibits Osteoclastogenesis and Periprosthetic Osteolysis by Suppressing the NF-κB and P38 MAPK Signaling Pathways |
Search more.